Federal Procurement Forecast
Whole-person Assessment of Response and Risk after transformative therapies: Investigating Outcomes and Resilience in Sickle Cell Disease (WARRIOR-SCD)
Forecast overview
- Subagency
- NIH
- NAICS
- 541715
- Known incumbent
- Medical College of Wisconsin
- Program office
- 75N980
The National Heart, Lung, and Blood Institute (NHLBI) requires contractor support to continue building a cohort of individuals with sickle cell disease (SCD) who have received gene therapy (GT) or hematopoietic cell transplantation (HCT) and to sustain long-term follow-up (LTFU) activities for enrolled participants. While both therapies are available, it has not been established which is safer, more durable, or most effective, nor have rigorous comparisons to untreated persons with SCD who have chosen not to undergo one of these treatments undertaken.
Related federal terms
- NAICS — North American Industry Classification System
Acquisition timeline
- Last verified on RFPCapture
- 2026-08-31
- Estimated solicitation
- 5/2027 (agency estimate)
- Estimated award
- 4/2028 (agency estimate)
- Expected period of performance end
- 4/2028 (agency estimate)
Why watch this
- This forecast is tied to an agency with active procurement in this NAICS.
- Recent awards exist in this market.
- The agency forecast names a known incumbent contractor.
- Recompete context: Related award history found; treat as related public awards unless SAM.gov confirms a recompete.
Market context
- NAICS market
- NAICS 541715
- Active contractors in this market
- 5 with relevant federal experience
- Recent comparable awards
- 8 from public USAspending records
- Known incumbent (source forecast)
- Medical College of Wisconsin
- Agency spending trend
- $238.6M · Declining
Contractors with relevant federal experience
Action links
Track this forecast in CaptureIQ
Source
- Source
- HHS SBCX Forecast Export
- Source file
- Forecast.csv
- Official source
- Agency forecast source
- Last verified
- 2026-08-31